Glenmark Pharmaceuticals rises on receiving ANDA approval for Rufinamide Tablets

19 May 2016 Evaluate

Glenmark Pharmaceuticals is currently trading at Rs. 862.10, up by 12.20 points or 1.44% from its previous closing of Rs. 849.90 on the BSE.

The scrip opened at Rs. 855.00 and has touched a high and low of Rs. 861.90 and Rs. 855.00 respectively. So far 1,203 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1261.95 on 21-Aug-2015 and a 52 week low of Rs. 671.50 on 12-Feb-2016.

Last one week high and low of the scrip stood at Rs. 884.50 and Rs. 842.85 respectively. The current market cap of the company is Rs. 24,319.00 crore.

The promoters holding in the company stood at 46.48% while Institutions and Non-Institutions held 41.92% and 11.60% respectively.

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for its Rufinamide Tablets USP, 200 mg and 400 mg, a therapeutic equivalent of Banzel Tablets, 200 mg and 400 mg of Eisai, Inc. According to IMS Health sales data for the 12 month period ending March 2016, the Banzel market achieved annual sales of approximately $155.1 million.

With respect to 180-day generic drug exclusivity, Glenmark was one of the first ANDA applicants to submit a substantially complete ANDA for Rufinamide Tablets USP, 200 mg and 400 mg, with a paragraph IV certification. Therefore, with this approval, Glenmark is eligible for 180 days of shared generic drug exclusivity for Rufinamide Tablets USP, 200 mg and 400 mg.

Glenmark’s current portfolio consists of 113 products authorized for distribution in the U.S. marketplace and 63 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.


Glenmark Pharma Share Price

1970.75 -25.15 (-1.26%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×